ClinicalTrials.govpublic full text
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
hematologic diseases, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, hematologic disorder, aml, high-risk myelodysplastic syndrome, hr-mds, cml, ondansetron, zofran, aprepitant
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 830046
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.